NASDAQ:KDMN

Kadmon Competitors

$3.62
-0.06 (-1.63 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.53
Now: $3.62
$3.71
50-Day Range
$3.58
MA: $4.25
$4.95
52-Week Range
$3.14
Now: $3.62
$5.73
Volume3.25 million shs
Average Volume3.76 million shs
Market Capitalization$621.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68

Competitors

Kadmon (NASDAQ:KDMN) Vs. FOLD, LGND, CYRX, XNCR, RCUS, and ALXO

Should you be buying KDMN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kadmon, including Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Cryoport (CYRX), Xencor (XNCR), Arcus Biosciences (RCUS), and ALX Oncology (ALXO).

Amicus Therapeutics (NASDAQ:FOLD) and Kadmon (NASDAQ:KDMN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Amicus Therapeutics and Kadmon, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amicus Therapeutics07602.46
Kadmon00503.00

Amicus Therapeutics presently has a consensus price target of $20.0385, suggesting a potential upside of 115.24%. Kadmon has a consensus price target of $12.75, suggesting a potential upside of 252.21%. Given Kadmon's stronger consensus rating and higher probable upside, analysts clearly believe Kadmon is more favorable than Amicus Therapeutics.

Valuation and Earnings

This table compares Amicus Therapeutics and Kadmon's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$182.24 million13.50$-356,390,000.00($1.31)-7.11
Kadmon$5.09 million122.20$-61,370,000.00($0.74)-4.89

Kadmon has lower revenue, but higher earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Kadmon, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

94.8% of Kadmon shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Amicus Therapeutics and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amicus Therapeutics-120.18%-73.81%-36.10%
Kadmon-768.36%-85.07%-46.46%

Volatility and Risk

Amicus Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Kadmon beats Amicus Therapeutics on 9 of the 14 factors compared between the two stocks.

Kadmon (NASDAQ:KDMN) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Kadmon and Ligand Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kadmon00503.00
Ligand Pharmaceuticals01502.83

Kadmon currently has a consensus target price of $12.75, suggesting a potential upside of 252.21%. Ligand Pharmaceuticals has a consensus target price of $215.60, suggesting a potential upside of 46.67%. Given Kadmon's stronger consensus rating and higher possible upside, research analysts plainly believe Kadmon is more favorable than Ligand Pharmaceuticals.

Earnings and Valuation

This table compares Kadmon and Ligand Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kadmon$5.09 million122.20$-61,370,000.00($0.74)-4.89
Ligand Pharmaceuticals$120.28 million20.30$629.30 million$2.1169.67

Ligand Pharmaceuticals has higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kadmon has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Profitability

This table compares Kadmon and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kadmon-768.36%-85.07%-46.46%
Ligand Pharmaceuticals-11.23%5.90%3.22%

Insider and Institutional Ownership

94.8% of Kadmon shares are owned by institutional investors. 3.0% of Kadmon shares are owned by insiders. Comparatively, 10.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ligand Pharmaceuticals beats Kadmon on 7 of the 13 factors compared between the two stocks.

Kadmon (NASDAQ:KDMN) and Cryoport (NASDAQ:CYRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares Kadmon and Cryoport's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kadmon$5.09 million122.20$-61,370,000.00($0.74)-4.89
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07

Cryoport has higher revenue and earnings than Kadmon. Cryoport is trading at a lower price-to-earnings ratio than Kadmon, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.8% of Kadmon shares are owned by institutional investors. Comparatively, 88.3% of Cryoport shares are owned by institutional investors. 3.0% of Kadmon shares are owned by insiders. Comparatively, 11.5% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Kadmon and Cryoport, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kadmon00503.00
Cryoport00703.00

Kadmon currently has a consensus target price of $12.75, suggesting a potential upside of 252.21%. Cryoport has a consensus target price of $72.00, suggesting a potential upside of 37.69%. Given Kadmon's higher possible upside, equities analysts clearly believe Kadmon is more favorable than Cryoport.

Risk and Volatility

Kadmon has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Profitability

This table compares Kadmon and Cryoport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kadmon-768.36%-85.07%-46.46%
Cryoport-55.87%-17.68%-11.32%

Summary

Cryoport beats Kadmon on 8 of the 13 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and Kadmon (NASDAQ:KDMN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Insider and Institutional Ownership

94.8% of Kadmon shares are held by institutional investors. 3.7% of Xencor shares are held by insiders. Comparatively, 3.0% of Kadmon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Xencor and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-113.40%-13.56%-12.03%
Kadmon-768.36%-85.07%-46.46%

Valuation and Earnings

This table compares Xencor and Kadmon's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million14.87$26.88 million$0.4687.41
Kadmon$5.09 million122.20$-61,370,000.00($0.74)-4.89

Xencor has higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Xencor has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Xencor and Kadmon, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor20702.56
Kadmon00503.00

Xencor presently has a consensus price target of $47.1111, suggesting a potential upside of 17.16%. Kadmon has a consensus price target of $12.75, suggesting a potential upside of 252.21%. Given Kadmon's stronger consensus rating and higher possible upside, analysts plainly believe Kadmon is more favorable than Xencor.

Summary

Xencor beats Kadmon on 8 of the 14 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Kadmon (NASDAQ:KDMN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares Arcus Biosciences and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
Kadmon-768.36%-85.07%-46.46%

Valuation & Earnings

This table compares Arcus Biosciences and Kadmon's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million153.33$-84,710,000.00($1.93)-16.81
Kadmon$5.09 million122.20$-61,370,000.00($0.74)-4.89

Kadmon has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Kadmon, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Arcus Biosciences and Kadmon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
Kadmon00503.00

Arcus Biosciences currently has a consensus price target of $49.9091, suggesting a potential upside of 53.80%. Kadmon has a consensus price target of $12.75, suggesting a potential upside of 252.21%. Given Kadmon's higher possible upside, analysts clearly believe Kadmon is more favorable than Arcus Biosciences.

Insider & Institutional Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 94.8% of Kadmon shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by insiders. Comparatively, 3.0% of Kadmon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Arcus Biosciences has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.

Summary

Arcus Biosciences beats Kadmon on 7 of the 13 factors compared between the two stocks.

ALX Oncology (NASDAQ:ALXO) and Kadmon (NASDAQ:KDMN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares ALX Oncology and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
Kadmon-768.36%-85.07%-46.46%

Insider and Institutional Ownership

73.5% of ALX Oncology shares are owned by institutional investors. Comparatively, 94.8% of Kadmon shares are owned by institutional investors. 3.0% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for ALX Oncology and Kadmon, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
Kadmon00503.00

ALX Oncology currently has a consensus target price of $90.6667, suggesting a potential upside of 58.81%. Kadmon has a consensus target price of $12.75, suggesting a potential upside of 252.21%. Given Kadmon's higher possible upside, analysts plainly believe Kadmon is more favorable than ALX Oncology.

Valuation & Earnings

This table compares ALX Oncology and Kadmon's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
Kadmon$5.09 million122.20$-61,370,000.00($0.74)-4.89

ALX Oncology has higher earnings, but lower revenue than Kadmon.

Ad The Gold Letter
The Dark Side Of The Electric Vehicle Boom
There's not enough of this valuable resource to meet demand. But this company might change that...

Kadmon Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.31-0.2%$2.46 billion$182.24 million-8.10Analyst Upgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.00-1.4%$2.44 billion$120.28 million-148.48Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$52.29-1.2%$2.38 billion$33.94 million-90.16
Xencor logo
XNCR
Xencor
1.2$40.21-1.5%$2.33 billion$156.70 million-28.72
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$32.45-6.0%$2.30 billion$15 million-16.99Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.09-1.5%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.04-0.6%$2.20 billion$963.01 million13.68
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.83-2.4%$2.05 billion$23.90 million-16.66Analyst Report
Analyst Revision
Amarin logo
AMRN
Amarin
1.6$5.08-15.0%$2.00 billion$429.76 million-101.58Gap Up
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.79-0.4%$1.98 billion$410,000.00-6.04
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.71-0.3%$1.93 billionN/A-19.22
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$21.00-4.0%$1.92 billion$34.51 million-17.95
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.27-0.3%$1.91 billionN/A-26.50Increase in Short Interest
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$45.66-11.5%$1.87 billionN/A0.00Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.43-0.4%$1.87 billion$103.54 million-18.37Insider Selling
MORF
Morphic
1.1$57.66-0.1%$1.87 billion$16.98 million-36.96Insider Selling
Decrease in Short Interest
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$115.57-1.3%$1.85 billionN/A-10.44
Kura Oncology logo
KURA
Kura Oncology
1.6$27.52-4.0%$1.82 billionN/A-16.88
FibroGen logo
FGEN
FibroGen
1.8$19.73-0.8%$1.81 billion$256.58 million-7.56Analyst Report
News Coverage
Gap Up
MacroGenics logo
MGNX
MacroGenics
1.4$29.57-1.7%$1.77 billion$64.19 million-9.45Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.76-0.2%$1.73 billion$1.63 billion14.05Decrease in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.91-0.3%$1.71 billion$26.87 million-12.52Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.31-1.5%$1.66 billion$428.41 million14.94News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.29-10.6%$1.66 billion$392.76 million12.98Analyst Upgrade
High Trading Volume
News Coverage
Gap Down
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.79-1.2%$1.63 billion$320,000.00-8.70Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.46-0.9%$1.62 billionN/A0.00High Trading Volume
Analyst Revision
uniQure logo
QURE
uniQure
1.7$34.88-5.0%$1.57 billion$7.28 million-9.25
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.73-0.1%$1.57 billion$2.34 million-9.63
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.07-0.6%$1.55 billionN/A-6.07High Trading Volume
Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.66-2.2%$1.52 billion$145.97 million-6.74
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$25.03-2.0%$1.51 billion$175.34 million-14.72Analyst Report
Analyst Revision
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.47-0.7%$1.51 billionN/A0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.4$64.05-8.4%$1.49 billionN/A0.00Increase in Short Interest
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.72-5.0%$1.47 billionN/A0.00Insider Selling
Increase in Short Interest
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.27-1.2%$1.45 billion$82.27 million-17.73
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$36.03-0.2%$1.44 billionN/A-150.13
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.67-3.6%$1.43 billionN/A0.00
Generation Bio logo
GBIO
Generation Bio
1.8$25.39-2.6%$1.43 billionN/A0.00Increase in Short Interest
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.79-2.1%$1.42 billion$6.20 million-14.38
ATBPD
Antibe Therapeutics
0.1$3.66-6.0%$1.42 billion$7.51 million-6.10
Endo International logo
ENDP
Endo International
1.5$6.11-1.0%$1.41 billion$2.91 billion-8.99
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.81-2.6%$1.39 billionN/A-3.01
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$27.49-3.2%$1.37 billion$19.89 million-12.97
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.46-3.8%$1.37 billion$4.23 million-19.60Increase in Short Interest
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.58-0.1%$1.34 billion$73.41 million-4.35Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$32.11-4.2%$1.34 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$36.37-5.0%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$32.48-2.3%$1.30 billionN/A0.00Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.